WO2023209677A2 - A novel aryl azo pyrazole compound and its synthesis - Google Patents
A novel aryl azo pyrazole compound and its synthesis Download PDFInfo
- Publication number
- WO2023209677A2 WO2023209677A2 PCT/IB2023/054469 IB2023054469W WO2023209677A2 WO 2023209677 A2 WO2023209677 A2 WO 2023209677A2 IB 2023054469 W IB2023054469 W IB 2023054469W WO 2023209677 A2 WO2023209677 A2 WO 2023209677A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mixture
- hydrazono
- stirring
- bromophenyl
- Prior art date
Links
- -1 aryl azo pyrazole compound Chemical class 0.000 title claims abstract description 41
- 230000015572 biosynthetic process Effects 0.000 title abstract description 4
- 238000003786 synthesis reaction Methods 0.000 title abstract description 4
- 239000004599 antimicrobial Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 239000011541 reaction mixture Substances 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 claims description 3
- REKQLYUAUXYJSZ-UHFFFAOYSA-N 4-methoxybenzohydrazide Chemical compound COC1=CC=C(C(=O)NN)C=C1 REKQLYUAUXYJSZ-UHFFFAOYSA-N 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 235000010288 sodium nitrite Nutrition 0.000 claims description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 2
- 229940125833 compound 23 Drugs 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 239000002221 antipyretic Substances 0.000 abstract description 3
- 229940125716 antipyretic agent Drugs 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000002585 base Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000189150 Nigrospora Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940014425 exodus Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
Definitions
- the invention relates to a novel aryl azo pyrazole compound of formula (I-3), or a pharmaceutically acceptable salt thereof. Particular aspects of the invention relates to a method of synthesizing the compounds and the use of those compounds in treating, ameliorating, or preventing microbial infection and inflammation.
- Antimicrobial agents are natural or synthetic substances that kills or inhibits the growth of microorganisms such as bacteria, fungi and algae.
- the main objective of the present invention is to provide novel aryl azo pyrazole compound, having the following structural formula (I-3). Another objective of the present invention is to provide a process of synthesizing the novel aryl azo pyrazole compound of formula (I-3). Another objective of the present invention is to provide novel aryl azo pyrazole compound of formula (I-3) which can be used as an antimicrobial agent, anti- inflammatory agent and anti-pyretic agent. SUMMARY OF THE INVENTION The main aspect of the present invention is to provide a compound represented by the formula (I-3)
- Another aspect of the present invention is to provide the process for preparing the compound having formula (I-3).
- Another aspect of the present invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I-3), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
- the present invention relates to methods of synthesizing the compound of formula (I-3) and the use of it in treating, ameliorating, or preventing a microbial infection and inflammation.
- the compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulphate, phosphate, acid phosphate, iso-nicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, and ascorbate.
- non-toxic acid addition salts i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulphate, phosphate, acid phosphate, iso-nicotinate, acetate
- the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds.
- Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamine-(meglu mine), and the lower alkanol ammonium and other base salts of pharmaceutically acceptable organic amines.
- Suitable base salts are formed from bases which form non-toxic salts.
- Non-limiting examples of suitable base salts include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, Sodium, tromethamine and Zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
- Antimicrobial Agents that kills microorganisms or stops their growth. Microorganisms include bacteria, fungi, virus and parasite.
- Anti-inflammatory Agents are the drugs or substance that reduces inflammation (redness, swelling and pain) in the body.
- Antipyretic Agents are the drugs or substances that reduces fever in the body.
- the present invention provides a novel compound (E)- 4-(2-(4-bromophenyl)hydrazono)-1-(4-methoxybenzoyl)-3-methyl-1H-pyrazol- 5(4H)-one represented by the formula (I-3) or pharmaceutically acceptable salts thereof.
- a process for preparation of (E)-4-(2-(4- bromophenyl)hydrazono)-1-(4-methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one having formula (I-3) comprises the steps of: a) Preparation of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (Intermediate-1) comprising following steps: i. Dissolving 70g of 4-bromoaniline in a 170 ml of 17% hydrochloric acid and 48 ml of methanol and cool the mixture at 0-5 o C under stirring. ii.
- step (i) Refluxing the solution of step (i) under stirring for 4-5 hours.
- iii. Cooling the mixture of step (ii) to 25-30 o C and continuously stirring at same temperature for 1 hour.
- iv. Filtering the crystallized compound of step (iii) and washing it with 80ml of cold toluene.
- v. Drying the compound of step (iv) under reduced pressure at 45- 50 o C to get 30.0g of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one Formula (I- 3).
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I-3), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
- Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art.
- the pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, and suspension, for parenteral injection as a sterile solution, suspension, or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight of the active ingredient, and, from 1 to 99.95% by weight, more preferably from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all percentages being based on the total composition.
- the pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.
- the present invention relates to methods of synthesizing the compound of formula (I-3) and the use of it in treating, ameliorating, or preventing a microbial infection and inflammation.
- the present invention relates to methods of synthesizing the compound of formula (I-3), wherein the compound exhibit Prostaglandin-E2 Synthase-1 inhibitors and non-opioids analgesic activity.
- Compounds described herein may be in various forms, including but not limited to, amorphous forms, milled forms and nano-particulate forms.
- compounds described herein include crystalline forms, also known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility.
- Example 1 Preparation of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3): a) The process for preparation of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (intermediate-1) comprises the following steps: i.
- ii. Dissolving 31g of sodium nitrite in 150ml of water and dropwise add the mixture in mixture of step (i).
- iii. Stirring the mixture of step (ii) at 0-5 o C for 30 minutes.
- Adding 53.2g of ethyl acetoacetate to the solution of step (iv) and cooling the mixture to -5-0 o C.
- step (v) Dropwise adding the mixture of step (v) to that of the mixture of step (iii) while keeping the temperature below 0-5 o C for 30 minutes.
- step (vi) Stirring the reaction mixture of step (vi) at below 5 o C for 30 minutes.
- step (viii) Filtering the reaction mixture of step (vii) and washing the precipitates with 2500ml of cold water.
- step (viii) Drying the compound of step (viii) under vacuum at 45-50 o C to get 125.5 g of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3-oxobutanoate (Intermediate -1).
- step (i) Refluxing the solution of step (i) under stirring for 4-5 hours.
- iii. Cooling the mixture of step (ii) to 25-300C and continuously stirring at same temperature for 1 hour.
- iv. Filtering the crystallized compound of step (iii) and washing it with 80ml of cold toluene.
- v. Drying the compound of step (iv) under reduced pressure at 45-500C to get 30.0g of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3).
- Example 2 Analysis of the compound The chemical formula of the compound i.
- the fungicidal activity of compound I-3 was studied at 1000 ppm concentration in vitro.
- Plant pathogenic organisms used were Aspergillus Niger, Nigrospora Species, Rhizopus Nigricum, Botrydepladia Theobromae and Fusarium Oxyporium.
- Such a Potato agar medium contained dextrose 20g, potato 200g, agar 20g and water 10 ml.
- the Compounds to be tested were hovering (1000 ppm) in a PDA medium and autoclaved at 100 °C for 14 minutes at 12 atm. pressure. Old cultures were employed five or more days.
- Nutrient agar broth was added in an aqueous beaker and boiled to 55 °C with occasional shaking to form well mixing. The melted mass was allowed to mix (1.5 hour) and after the mixing the “cups” were made by pressing into the agar with spooning out the pressed part of agar and sterile cork borer. Into this cups 0.10 ml of prepared test solution (prepared by dissolving 10.0 gm of sample in 10 ml Dimethyl formamide) was added by micropipette which was sterile. The plates were noted by appropriate codes.
- Example 3 Oral Toxicity Study Acute oral toxicity for the compound with Formula (I-3) was done to study of adverse effects of a test item that results either from a single oral exposure or from multiple exposures within 24 hours. The study was conducted on 9 female Wistar Rats that are 8-12 weeks old in age. The animals were subjected to 12 hours light and 12 hours dark cycle maintaining the temperature at 20 – 24.3°C and relative humidity of 49-64%. Treatment Procedure: Animals were fasted overnight before the treatment. The dose volume was calculated based on individual animal body weight. The test item was administered orally.
- test item administered After the test item administered, animals were fasted for further 3-4 hours. Single animal was dosed in sequence usually at 48 hours intervals based on AOT 425 Software and as per the selected slope. As the animal survives, the second animal was receiving a higher dose until the stopping criteria met.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to novel aryl azo pyrazole compound, having the following structural formula (I-3) which can be used as antimicrobial, anti-inflammatory and antipyretic agent. The present invention also provides novel process for synthesis of novel aryl azo pyrazole compound of structural formula (I-3).
Description
NOVEL ARYL AZO PYRAZOLE COMPOUND AND ITS SYNTHESIS FIELD OF THE INVENTION The invention relates to a novel aryl azo pyrazole compound of formula (I-3), or a pharmaceutically acceptable salt thereof. Particular aspects of the invention relates to a method of synthesizing the compounds and the use of those compounds in treating, ameliorating, or preventing microbial infection and inflammation.
BACKGROUND OF THE INVENTION Antimicrobial agents are natural or synthetic substances that kills or inhibits the growth of microorganisms such as bacteria, fungi and algae. The production and use of the antibiotic penicillin in the early 1940s became the basis for the era of modern antimicrobial therapy and since then many antibiotics and other types of antimicrobials have been found. Major discovery following the introduction of these agents into medicine was the finding that their basic structure could be modified chemically to improve their characteristics. Widespread use of antimicrobial agents in recent decades has led to proliferation of pathogens having multiple drug resistance, often encoded by transmissible plasmids, and therefore capable of spreading rapidly between species. Many previously useful antimicrobial agents are no longer effective against infectious organisms isolated from human and animal subjects. The spectre of epidemic forms of bacterial diseases such as tuberculosis and fungal diseases, which are refractory to known antibiotic agents, may be realized in the near future. Development of novel antimicrobial compounds is a continuing urgent public health need.
The discovery and development of new antimicrobial agents have been for decades a major focus of many pharmaceutical companies. Nonetheless, in more recent years there has been an exodus from this area of research and drug development resulting in very few new antimicrobials entering the market. This lack of new antimicrobial is particularly disturbing, especially at a time when bacterial resistance to current therapies is increasing both in the hospital and community settings. Thus, there is a need to develop new antimicrobial compounds. The present invention arose due to the inventor's interest in pyrazole heterocyclic moiety and developed novel aryl azo pyrazole compound as Antimicrobial and Antifungal Agent. OBJECTIVE OF THE INVENTION The main objective of the present invention is to provide novel aryl azo pyrazole compound, having the following structural formula (I-3).
Another objective of the present invention is to provide a process of synthesizing the novel aryl azo pyrazole compound of formula (I-3). Another objective of the present invention is to provide novel aryl azo pyrazole compound of formula (I-3) which can be used as an antimicrobial agent, anti- inflammatory agent and anti-pyretic agent. SUMMARY OF THE INVENTION The main aspect of the present invention is to provide a compound represented by the formula (I-3)
Another aspect of the present invention is to provide the process for preparing the compound having formula (I-3). Another aspect of the present invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I-3), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. In another embodiment, the present invention relates to methods of synthesizing the compound of formula (I-3) and the use of it in treating, ameliorating, or preventing a microbial infection and inflammation. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1: FTIR Sprectra of compound (I-3) Figure 2.1: Mass Sprectra of compound (I-3) (+ve ion) Figure 2.2: Mass Sprectra of compound (I-3) (-ve ion) Figure 3: 1H NMR Sprectra of compound (I-3) DESCRIPTION OF THE INVENTION The present invention is about aryl azo pyrazole compound as antimicrobial agent, as described herein. The phrase “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the present invention.
The compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulphate, phosphate, acid phosphate, iso-nicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, and ascorbate. Succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, Saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate i.e., 1,1'- methylene-bis-(2- hydroxy-3-naphthoate) salts. The compounds of the present invention that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. The invention also relates to base addition salts of the compounds of the invention. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamine-(meglu mine), and the lower alkanol ammonium and other base salts of pharmaceutically acceptable organic amines. Suitable base salts are formed from bases which form non-toxic salts. Non-limiting examples of suitable base salts include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, Sodium, tromethamine and Zinc salts. Hemisalts
of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. The phrase “Antimicrobial Agents” that kills microorganisms or stops their growth. Microorganisms include bacteria, fungi, virus and parasite. The phrase “Anti-inflammatory Agents” are the drugs or substance that reduces inflammation (redness, swelling and pain) in the body. The phrase “Antipyretic Agents” are the drugs or substances that reduces fever in the body. As per the main embodiment, the present invention provides a novel compound (E)- 4-(2-(4-bromophenyl)hydrazono)-1-(4-methoxybenzoyl)-3-methyl-1H-pyrazol- 5(4H)-one represented by the formula (I-3) or pharmaceutically acceptable salts thereof.
As per another main embodiment, a process for preparation of (E)-4-(2-(4- bromophenyl)hydrazono)-1-(4-methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one having formula (I-3) comprises the steps of: a) Preparation of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (Intermediate-1) comprising following steps: i. Dissolving 70g of 4-bromoaniline in a 170 ml of 17% hydrochloric acid and 48 ml of methanol and cool the mixture at 0-5ºC under stirring. ii. Dissolving 31g of sodium nitrite in 150ml of water and dropwise add the mixture in mixture of step (i).
iii. Stirring the mixture of step (ii) at 0-5ºC for 30 minutes. iv. Dissolving 130g of sodium acetate in 200 ml of water and stirring the mixture to get a clear solution and cooling the solution to 0-5ºC. v. Adding 53.2g of ethyl acetoacetate to the solution of step (iv) and cooling the mixture to -5-0ºC. vi. Dropwise adding the mixture of step (v) to that of the mixture of step (iii) to get the white precipitate of product while keeping the temperature below 0-5ºC for 30 minutes. vii. Stirring the reaction mixture of step (vi) at below 5ºC for 30 minutes. viii. Filtering the reaction mixture of step (vii) and washing the precipitates with 2500ml of cold water. ix. Drying the compound of step (viii) under vacuum at 45-50ºC to get 125.5 g of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (Intermediate -1). b) Preparation of ethyl 2-(2-(4-bromophenyl)hydrazono)-3-(2-(4- methoxybenzoyl)hydrazono)butanoate (Intermediate-2) comprising following steps: i. Dissolving 31.3g of Intermediate-1 and 16.6g of 4- methoxybenzohydrazide into 100ml of acetic acid at room temperature. ii. Stirring the reaction mixture of step (i) at 25-30ºC for 2-3 hours (After 1 hour the reaction mixture becomes clear solution and then precipitation occurs after 2 hours). iii. Cooling the reaction mixture of step (ii) to 20-25ºC and stirring at same temperature for 1 hour. iv. Filtering the precipitated compound of step (iii) and washing it with cold water (2 X 50 mL).
v. Drying the compound of step (iv) at 45-50ºC to get 36.6 g of ethyl 2-(2-(4-bromophenyl)hydrazono)-3-(2-(4- methoxybenzoyl)hydrazono)butanoate (Intermediate-2). c) Preparation of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3) comprising following steps: i. Dissolving 36.0g of Intermediate-2 in 360.0ml of toluene and stirring the mixture at room temperature. ii. Refluxing the solution of step (i) under stirring for 4-5 hours. iii. Cooling the mixture of step (ii) to 25-30ºC and continuously stirring at same temperature for 1 hour. iv. Filtering the crystallized compound of step (iii) and washing it with 80ml of cold toluene. v. Drying the compound of step (iv) under reduced pressure at 45- 50ºC to get 30.0g of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one Formula (I- 3). The complete reaction scheme of the synthesis of derivatives of the present invention is as follows:
In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I-3), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art. The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, and suspension, for parenteral injection as a sterile solution, suspension, or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight of the active ingredient, and, from 1 to 99.95% by weight, more preferably from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all percentages being based on the total composition. The pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant. In another embodiment, the present invention relates to methods of synthesizing the compound of formula (I-3) and the use of it in treating, ameliorating, or preventing a microbial infection and inflammation.
In another embodiment, the present invention relates to methods of synthesizing the compound of formula (I-3), wherein the compound exhibit Prostaglandin-E2 Synthase-1 inhibitors and non-opioids analgesic activity. Compounds described herein may be in various forms, including but not limited to, amorphous forms, milled forms and nano-particulate forms. In addition, compounds described herein include crystalline forms, also known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors such as the recrystallization Solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate. EXAMPLES The following working examples represent preferred embodiments of the present invention. All temperatures are expressed in degrees Centigrade unless otherwise indicated. Example 1: Preparation of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3): a) The process for preparation of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (intermediate-1) comprises the following steps:
i. Dissolving 70g of 4-bromoaniline in a 170 ml of hydrochloric acid and 48 ml of methanol and cool the mixture at 0-5ºC under stirring.
ii. Dissolving 31g of sodium nitrite in 150ml of water and dropwise add the mixture in mixture of step (i). iii. Stirring the mixture of step (ii) at 0-5ºC for 30 minutes. iv. Dissolving 130g of sodium acetate in 200 ml of water and stirring the mixture to get a clear solution and cooling the solution to 0-5ºC. v. Adding 53.2g of ethyl acetoacetate to the solution of step (iv) and cooling the mixture to -5-0ºC. vi. Dropwise adding the mixture of step (v) to that of the mixture of step (iii) while keeping the temperature below 0-5ºC for 30 minutes. vii. Stirring the reaction mixture of step (vi) at below 5ºC for 30 minutes. viii. Filtering the reaction mixture of step (vii) and washing the precipitates with 2500ml of cold water. ix. Drying the compound of step (viii) under vacuum at 45-50ºC to get 125.5 g of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3-oxobutanoate (Intermediate -1). b) Preparation of ethyl 2-(2-(4-bromophenyl)hydrazono)-3-(2-(4- methoxybenzoyl)hydrazono)butanoate (Intermediate-2) comprising following steps:
i. Dissolving 31.3g of Intermediate-1 and 16.6g of 4- methoxybenzohydrazide into 100ml of acetic acid at room temperature. ii. Stirring the reaction mixture of step (i) at 25-300C for 2-3 hours. iii. Cooling the reaction mixture of step (ii) to 20-250C and stirring at same temperature for 1 hour.
iv. Filtering the precipitated compound of step (iii) and washing it with 100ml of cold water. v. Drying the compound of step (iv) at 45-500C to get 36.6 g of ethyl 2-(2-(4-bromophenyl)hydrazono)-3-(2-(4- methoxybenzoyl)hydrazono)butanoate (Intermediate-2). c) Preparation of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3) comprising following steps:
i. Dissolving 36.0g of Intermediate-2 in 360.0ml of toluene and stirring the mixture at room temperature. ii. Refluxing the solution of step (i) under stirring for 4-5 hours. iii. Cooling the mixture of step (ii) to 25-300C and continuously stirring at same temperature for 1 hour. iv. Filtering the crystallized compound of step (iii) and washing it with 80ml of cold toluene. v. Drying the compound of step (iv) under reduced pressure at 45-500C to get 30.0g of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3). Example 2: Analysis of the compound The chemical formula of the compound i. (E)-4-(2-(4- bromophenyl)hydrazono)-1-(4-methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3) is C18H15BrN4O3 having the molecular weight 415.24. Figure 1 illustrates FTIR spectra, Figure 2.1 and 2.2 illustrates Mass spectra, and Figure 3 illustrates 1H NMR spectra of compound 23.
Example 3: Biological Evaluation Antifungal activity: The biological activity such as antifungal activity of compound I-3 was tested on a potato dextrose agar (PDA) medium on each of these vegetable pathogenic strains. The fungicidal activity of compound I-3 was studied at 1000 ppm concentration in vitro. Plant pathogenic organisms used were Aspergillus Niger, Nigrospora Species, Rhizopus Nigricum, Botrydepladia Theobromae and Fusarium Oxyporium. Such a Potato agar medium contained dextrose 20g, potato 200g, agar 20g and water 10 ml. The Compounds to be tested were hovering (1000 ppm) in a PDA medium and autoclaved at 100 °C for 14 minutes at 12 atm. pressure. Old cultures were employed five or more days. These Potato agar media were mixed into sterile Petri plates and the microorganisms were immunized after cooling the Petri plates. The % zonal inhibition calculated for fungi was after five days using the formula given below: % of inhibition = 100 (X-Y) / X Where, Y = test plate Area of colony X = control plate Area of colony Table 1: Antifungal activity of 4-[4-Methoxybenzoyl]-3-methyl-1-(4- bromophenyl)-2-pyrazoline -5-one (Compound I-3)
Antibacterial activity:
It was mixed with 0.3-0.8 ml of 48 hour mixed well and old culture especially by normal stirring before adding on the Petri dish sterilized (50 ml in each dish). Nutrient agar broth was added in an aqueous beaker and boiled to 55 °C with occasional shaking to form well mixing. The melted mass was allowed to mix (1.5 hour) and after the mixing the “cups” were made by pressing into the agar with spooning out the pressed part of agar and sterile cork borer. Into this cups 0.10 ml of prepared test solution (prepared by dissolving 10.0 gm of sample in 10 ml Dimethyl formamide) was added by micropipette which was sterile. The plates were noted by appropriate codes. Table 2: Antibacterial activity of 4-[4-Methoxybenzoyl]-3-methyl-1-(4- bromophenyl)-2-pyrazoline -5-one (Compound I-3)
Example 3: Oral Toxicity Study Acute oral toxicity for the compound with Formula (I-3) was done to study of adverse effects of a test item that results either from a single oral exposure or from multiple exposures within 24 hours. The study was conducted on 9 female Wistar Rats that are 8-12 weeks old in age. The animals were subjected to 12 hours light and 12 hours dark cycle maintaining the temperature at 20 – 24.3°C and relative humidity of 49-64%.
Treatment Procedure: Animals were fasted overnight before the treatment. The dose volume was calculated based on individual animal body weight. The test item was administered orally. After the test item administered, animals were fasted for further 3-4 hours. Single animal was dosed in sequence usually at 48 hours intervals based on AOT 425 Software and as per the selected slope. As the animal survives, the second animal was receiving a higher dose until the stopping criteria met.
Results: The test compound of Formula I-3 administered by oral route and did not show any clinical sign and mortality/morbidity at any dose level under the tested conditions. Based on the results, the LD50 of the test compound of Formula I-3 for acute oral toxicity was found greater than 5000 mg/kg b.wt and stopping criteria met 3 consecutive animals survive at the upper bound/limit dose.
Claims
CLAIMS We claim, 1. A novel aryl azo pyrazole compound, comprising the formula (I-3),
or a pharmaceutically acceptable salt thereof. 2. A process for preparation of compound claimed in claim 1, comprising the following steps: a) Preparation of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (Intermediate-1) comprising following steps: i. Dissolving 70g of 4-bromoaniline in a 170 ml of 17% hydrochloric acid and 48 ml of methanol and cool the mixture at 0-5ºC under stirring. ii. Dissolving 31g of sodium nitrite in 150ml of water and dropwise add the mixture in mixture of step (i). iii. Stirring the mixture of step (ii) at 0-5ºC for 30 minutes. iv. Dissolving 130g of sodium acetate in 200 ml of water and stirring the mixture to get a clear solution and cooling the solution to 0-5ºC. v. Adding 53.2g of ethyl acetoacetate to the solution of step (iv) and cooling the mixture to -5-0ºC. vi. Dropwise adding the mixture of step (v) to that of the mixture of step (iii) to get the white precipitate of the compound while keeping the temperature below 0-5ºC for 30 minutes. vii. Stirring the reaction mixture of step (vi) at below 5ºC for 30 minutes.
viii. Filtering the reaction mixture of step (vii) and washing the precipitates with 2500ml of cold water. ix. Drying the compound of step (viii) under vacuum at 45-50ºC to get 125.5 g of (E)-ethyl 2-(2-(4-bromophenyl)hydrazono)-3- oxobutanoate (Intermediate -1). b) Preparation of ethyl 2-(2-(4-bromophenyl)hydrazono)-3-(2-(4- methoxybenzoyl)hydrazono)butanoate (Intermediate-2) comprising following steps: i. Dissolving 31.3g of Intermediate-1 and 16.6g of 4- methoxybenzohydrazide into 100ml of acetic acid at room temperature. ii. Stirring the reaction mixture of step (i) at 25-30ºC for 2-3 hours (After 1 hour the reaction mixture becomes clear solution and then precipitation occurs after 2 hours). iii. Cooling the reaction mixture of step (ii) to 20-25ºC and stirring at same temperature for 1 hour. iv. Filtering the precipitated compound of step (iii) and washing it with cold water (2 X 50 mL). v. Drying the compound of step (iv) at 45-50ºC to get 36.6 g of ethyl 2-(2-(4-bromophenyl)hydrazono)-3-(2-(4- methoxybenzoyl)hydrazono)butanoate (Intermediate-2). c) Preparation of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Formula I-3) comprising following steps: i. Dissolving 36.0g of Intermediate-2 in 360.0ml of toluene and stirring the mixture at room temperature. ii. Refluxing the solution of step (i) under stirring for 4-5 hours. iii. Cooling the mixture of step (ii) to 25-30ºC and continuously stirring at same temperature for 1 hour. iv. Filtering the crystallized compound of step (iii) and washing it with 80ml of cold toluene.
v. Drying the compound of step (iv) under reduced pressure at 45- 50ºC to get 30.0g of (E)-4-(2-(4-bromophenyl)hydrazono)-1-(4- methoxybenzoyl)-3-methyl-1H-pyrazol-5(4H)-one (Compound 23). 3. The novel aryl azo pyrazole compound as claimed in claim 1, wherein the said compound is used to prepare pharmaceutical composition comprising a pharmaceutically active compound of Formula (I-3), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. 4. The novel aryl azo pyrazole compound as claimed in claim 1, wherein the pharmaceutical composition is an anti-microbial agent for treating microbial infection. 5. The aryl azo pyrazole derivatives as claimed in claim 1, wherein the said derivatives having LD505000mg/kg.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202221025284 | 2022-04-29 | ||
IN202221025284 | 2022-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023209677A2 true WO2023209677A2 (en) | 2023-11-02 |
WO2023209677A3 WO2023209677A3 (en) | 2024-04-04 |
Family
ID=88518021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/054469 WO2023209677A2 (en) | 2022-04-29 | 2023-04-28 | A novel aryl azo pyrazole compound and its synthesis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023209677A2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2008148319A (en) * | 2006-05-09 | 2010-06-20 | Вокхардт Лтд (In) | SUBSTITUTED PIPERIDINOPHENYLOXAZOLIDINOINS |
US8420678B2 (en) * | 2008-04-14 | 2013-04-16 | Board Of Regents, The University Of Texas System | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
WO2011032169A2 (en) * | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
-
2023
- 2023-04-28 WO PCT/IB2023/054469 patent/WO2023209677A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023209677A3 (en) | 2024-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7410974B2 (en) | Halogenated Quinazolinyl nitrofurans as antibacterial agents | |
CN109867623B (en) | 3-pyridyl-3-amino-2-cyanoacrylate compounds and preparation method and application thereof | |
JPS5973575A (en) | Propynylaminoisoxazole derivative | |
CN110330489B (en) | Quinolone thiazole oxime compound and preparation method and application thereof | |
KR20060080817A (en) | A dicarboxylic acid salt of sibutramine | |
WO2023209677A2 (en) | A novel aryl azo pyrazole compound and its synthesis | |
TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
JPS63122681A (en) | Water-soluble adduct of norfloxasine | |
US3991210A (en) | Acetamidine urinary antiseptics | |
WO2023209678A1 (en) | Aryl azo pyrazole derivatives as antimicrobial agent | |
US4044130A (en) | Compositions for the control of microorganisms | |
US20080188499A1 (en) | Carbo- and Hetero-Cyclic Antibiotics and Use Thereof | |
KR100404714B1 (en) | Guanidinomethyl cyclohexane carboxylic ester derivative | |
US3790679A (en) | Urinary antiseptic method with thioacetamidines | |
TW200427458A (en) | Crystalline N-formyl hydroxylamine compounds | |
EP0812324B1 (en) | Aqueous spectinomycin borate solutions | |
CN112920168B (en) | New application of talpimod and derivative or pharmaceutically acceptable salt thereof and mycobacterium tuberculosis inhibitor | |
SU562978A1 (en) | Thiazolidine derivatives possessing antifungus activity and method of obtaining same | |
RU2785195C1 (en) | Method for production of polymorphous form of 4-(3-ethoxy-4-hydroxybenzyl)-n-(2,4-difluorphenyl)-5-oxo-5,6-dihydro-4h-1,3,4-thiadizine-2-carboxamide | |
US4069330A (en) | Nitropyrazole compounds and anti-microbial compositions | |
US4001265A (en) | 3,4-dimethyl-5-isoxazolylsulfamylaniline | |
US20220153767A1 (en) | Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof | |
UA72286C2 (en) | Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon | |
RU2161606C2 (en) | 9-benzylidenehydrazino-1,2,3,4-tetrahydroacridine showing analgetic and antibacterial activity against staphylococcus aureus | |
US20030236290A1 (en) | Inhibitors of animal cell motility and growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23795770 Country of ref document: EP Kind code of ref document: A2 |